Surgical Outcomes and Costs in Using the Shenzhen HugeMed 6.3 French Flexible Ureteroscope

ConditionKidney Stones
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity of Kansas Medical Center

About this trial

Comprehensive comparative investigations between HugeMed HU30M 6.3 Fr f-URS and traditional approach f-URS devices in RIRS are lacking in an American population. The investigators aim to compare the outcomes of using the 6.3 Fr f-URS versus traditional approach (other f-URS present in our institution) to treat patients with stone burden ≤ 2.5 cm. The findings of this study will expand on the potential advantages and drawbacks of HU30M in enhancing surgical outcomes and patient safety in RIRS procedures. We hypothesize that the use of the HU30M will result in increased cost savings while providing similar stone free rates when compared to traditionally used f-URS devices.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Males or females ≥ 18 years of age

Patients with ureteral or kidney stones undergoing primary flexible ureteroscopy for retrograde intrarenal surgery

Total stone burden ≤ 2.5 cm

Disqualifiers

Undergoing bilateral stone treatment during the same procedure

Patients with known genitourinary anatomical abnormalities that would complicate the procedure as determined by the treating investigator

Uncorrected coagulopathy

Patients with urinary diversions

Trial design

Design model

Single group

Treatments tested in this trial

  • Ureteroscopy using the 6.3 Fr f-URS hugemed

    Device

    All patients will be counseled on standard treatment options. Treatment options and subsequent care will not deviate from routine care. If they do not enroll in the study, the HU30M may still be used during routine surgery and care. The only intervention specific to the research will involve the use of patient information in describing the results. Participants will undergo RIRS in standard fashion, without deviation from the standard of care. Patients will be brought to the operating room, positioned, and placed under general anesthesia. RIRS will be performed using HU30M 6.3 Fr f-URS. Laser platform (ex: HoYAG or TFL) as well as laser settings will be at the treating investigator's discretion and may be changed during the procedure at their discretion as well, all per standard of care. The initial laser settings and changes that occurred to the settings after the first minute of the case will be recorded.

  • Hugemed 6.3 Fr f-URS

    Device

    Retrograde intrarenal surgery will be performed using HU30M 6.3 Fr f-URS.

Treatment groups

75 Participants
are divided into 1 treatment group
Group A: hugemed ureteroscopyActive comparator 2 interventions

Trial outcomes

Primary outcomes

1

To evaluate and compare outcomes and costs associated with hugeMed 6.3 Fr flexible URS versus traditional approach in RIRS

Stone free rate, defined as the absence of residual stone fragments \> 2 mm, as determined by noncontrast CT scan performed

Time frame
36 months

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.